Yannick Foerster
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yannick Foerster has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Oana-Diana Persa
Department of Dermatology and Allergy Biederstein, School of Medicine and Health, TUM University Hospital Technical University of Munich Munich Germany
20 shared publications - Tilo Biedermann
Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany
16 shared publications - Doris Helbig
Department of Dermatology and Venereology University Hospital Cologne Cologne Germany
15 shared publications - Ka-Won Noh
Institute of Pathology, University Hospital of Cologne and Medical Faculty, Cologne, Germany
15 shared publications - Max Schlaak
Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Dermatology, Venereology and Allergology, Berlin, Germany
15 shared publications - Reinhard Büttner
Center for Integrated Oncology Aachen Köln Bonn Düsseldorf, Germany
15 shared publications
Latest Publications
- Open Access
- 17 January 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (5) , 952-962
Sirolimus for Secondary Prevention of Cutaneous Squamous Cell Carcinoma in Kidney Transplant Recipients: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Kidney transplant recipients (KTRs) are at increased risk of developing cutaneous squamous cell carcinoma (cSCC), particularly when treated with calcineurin inhibitors (CNI), which are strongly associated with tumorigenesis. In contrast, mTOR inhibitors such as sirolimus have demonstrated antitumor activity, but their role in secondary prevention of cSCC remains unclear. We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) to evaluate the impact of switching from a CNI‐based to an mTOR inhibitor‐based immunosuppressive regimen on the incidence of cSCC in KTRs with prior cSCC. MEDLINE, EMBASE, CENTRAL, and trial registries were searched through June 2025. Incidence rate ratios (IRRs) for cSCC and risk ratios (RRs) for adverse events (AEs) were pooled using a random‐effects model. Risk of bias was assessed with Cochrane RoB2. The study was registered in PROSPERO prior to data extraction (CRD42024583966). The study was unfunded. Four RCTs (393 patients) were included. Sirolimus significantly reduced 2‐year cSCC incidence (IRR 0.51, 95% CI 0.39–0.67). However, discontinuation was more frequent (RR 8.60, 95% CI 1.95–37.93) due to AEs. No significant differences in mortality or graft rejection were found. Certainty of evidence was high for cSCC incidence and low for adverse events due to heterogeneity and selective reporting. In conclusion, sirolimus reduces secondary cSCC risk but increases AEs; patient selection and monitoring are essential. Trial Registration: PROSPERO number: CRD42024583966
- 17 January 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (5) , 952-962
Open AccessSirolimus for Secondary Prevention of Cutaneous Squamous Cell Carcinoma in Kidney Transplant Recipients: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Kidney transplant recipients (KTRs) are at increased risk of developing cutaneous squamous cell carcinoma (cSCC), particularly when treated with calcineurin inhibitors (CNI), which are strongly associated with tumorigenesis. In contrast, mTOR inhibitors such as sirolimus have demonstrated antitumor activity, but their role in secondary prevention of cSCC remains unclear. We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) to evaluate the impact of switching from a CNI‐based to an mTOR inhibitor‐based immunosuppressive regimen on the incidence of cSCC in KTRs with prior cSCC. MEDLINE, EMBASE, CENTRAL, and trial registries were searched through June 2025. Incidence rate ratios (IRRs) for cSCC and risk ratios (RRs) for adverse events (AEs) were pooled using a random‐effects model. Risk of bias was assessed with Cochrane RoB2. The study was registered in PROSPERO prior to data extraction (CRD42024583966). The study was unfunded. Four RCTs (393 patients) were included. Sirolimus significantly reduced 2‐year cSCC incidence (IRR 0.51, 95% CI 0.39–0.67). However, discontinuation was more frequent (RR 8.60, 95% CI 1.95–37.93) due to AEs. No significant differences in mortality or graft rejection were found. Certainty of evidence was high for cSCC incidence and low for adverse events due to heterogeneity and selective reporting. In conclusion, sirolimus reduces secondary cSCC risk but increases AEs; patient selection and monitoring are essential. Trial Registration: PROSPERO number: CRD42024583966
- Open Access
- 7 December 2025
- Published by Wiley in Experimental Dermatology
- Vol. 34 (12) , e70185
High ROR1 Expression Is Associated With Poor Differentiation and Perineural Invasion in Cutaneous Squamous Cell Carcinoma
Cutaneous squamous cell carcinoma (cSCC) is a common type of skin cancer, predominantly affecting elderly and immunosuppressed patients. Despite recent therapeutic advances, including the introduction of immune checkpoint inhibitors, outcomes for patients with metastatic or recurrent disease remain poor, underscoring the need for new therapeutic approaches and reliable biomarkers to identify patients at high risk of progression. In this context, receptor tyrosine kinase‐like orphan receptor 1 (ROR1), previously associated with poor prognosis and targeted therapeutically in other malignancies, has not yet been investigated in cSCC. This study aimed to evaluate ROR1 expression in cSCC and investigate its potential role as a biomarker for tumour aggressiveness. ROR1 expression was analysed via immunofluorescence in a tissue microarray of 360 cSCC samples from a biobank cohort at the University Hospital Cologne. Fluorescence intensity was quantified and correlated with clinicopathologic features and patient outcomes. High ROR1 expression was detected in 42.5% of samples, predominantly localised at tumour invasive fronts. Elevated ROR1 levels were significantly associated with poor tumour differentiation ( p < 0.001), lymph node metastasis ( p = 0.007), and perineural invasion ( p = 0.005). Although higher ROR1 expression correlated with worse progression‐free and metastasis‐free survival, these differences did not reach statistical significance. In conclusion, this study identifies ROR1 as a novel marker of aggressive cSCC, linked to poor differentiation, lymphatic spread and perineural invasion. ROR1 holds potential both as a prognostic biomarker and as a therapeutic target, encouraging future exploration of ROR1‐directed therapies in advanced cSCC.
- 7 December 2025
- Published by Wiley in Experimental Dermatology
- Vol. 34 (12) , e70185
Open AccessHigh ROR1 Expression Is Associated With Poor Differentiation and Perineural Invasion in Cutaneous Squamous Cell Carcinoma
Cutaneous squamous cell carcinoma (cSCC) is a common type of skin cancer, predominantly affecting elderly and immunosuppressed patients. Despite recent therapeutic advances, including the introduction of immune checkpoint inhibitors, outcomes for patients with metastatic or recurrent disease remain poor, underscoring the need for new therapeutic approaches and reliable biomarkers to identify patients at high risk of progression. In this context, receptor tyrosine kinase‐like orphan receptor 1 (ROR1), previously associated with poor prognosis and targeted therapeutically in other malignancies, has not yet been investigated in cSCC. This study aimed to evaluate ROR1 expression in cSCC and investigate its potential role as a biomarker for tumour aggressiveness. ROR1 expression was analysed via immunofluorescence in a tissue microarray of 360 cSCC samples from a biobank cohort at the University Hospital Cologne. Fluorescence intensity was quantified and correlated with clinicopathologic features and patient outcomes. High ROR1 expression was detected in 42.5% of samples, predominantly localised at tumour invasive fronts. Elevated ROR1 levels were significantly associated with poor tumour differentiation ( p < 0.001), lymph node metastasis ( p = 0.007), and perineural invasion ( p = 0.005). Although higher ROR1 expression correlated with worse progression‐free and metastasis‐free survival, these differences did not reach statistical significance. In conclusion, this study identifies ROR1 as a novel marker of aggressive cSCC, linked to poor differentiation, lymphatic spread and perineural invasion. ROR1 holds potential both as a prognostic biomarker and as a therapeutic target, encouraging future exploration of ROR1‐directed therapies in advanced cSCC.
- Open Access
- 14 November 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (11) , 1373-1386
Therapien des Morbus Bowen: Systematisches Review und Netzwerk‐Metaanalyse randomisierter kontrollierter Studien
Zusammenfassung: Morbus Bowen (MB) ist eine intraepidermale bösartige Neubildung, die zu einem invasiven Plattenepithelkarzinom der Haut führen kann. Bisher existiert keine Studie, die Therapieoptionen aus randomisierten kontrollierten Studien (RCT) miteinander verglichen hat. In dieser Arbeit wurden Daten aus verfügbaren RCT extrahiert, um läsionsspezifische Heilungsraten und kosmetische Ergebnisse mit Placebo zu vergleichen. Wir durchsuchten MEDLINE, EMBASE, CENTRAL und Studienregister bis 30. September 2024, und schlossen neun Studien mit 672 Patienten und 844 Läsionen ein. Die Therapieoptionen, welche mithilfe einer Netzwerk‐Metaanalyse verglichen wurden, umfassten: Exzision, Imiquimod, photodynamische Therapie (PDT), Laserablation (LA), lasergestützte PDT (LA‐PDT), Kryotherapie und 5‐Fluoruracil (5‐FU). Das Verzerrungsrisiko wurde mithilfe des überarbeiteten Cochrane risk‐of‐bias Tool evaluiert. Die Studie wurde in PROSPERO registriert (CRD42024583966). Alle Therapieoptionen zeigten bessere läsionsspezifische Heilungsraten als Placebo. Bezüglich der initialen Heilungsrate zeigte LA‐PDT die besten Ergebnisse, gefolgt von Exzision und LA. Die Exzision zeigte die besten Ergebnisse bezüglich der langfristigen Heilungsrate, gefolgt von LA‐PDT und PDT. LA‐PDT und 5‐FU hatten das beste, die Exzision das schlechteste kosmetische Ergebnis. Limitationen umfassen ein moderates bis hohes Verzerrungsrisiko sowie Heterogenität der Einzelstudien. Unsere Ergebnisse unterstützen die klinische Entscheidungsfindung, wobei sich LA‐PDT und PDT als effektive Optionen bei guten kosmetischen Ergebnissen erwiesen haben. Die Exzision zeigte jedoch die besten langfrisigen Heilungsraten.
- 14 November 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (11) , 1373-1386
Open AccessTherapien des Morbus Bowen: Systematisches Review und Netzwerk‐Metaanalyse randomisierter kontrollierter Studien
Zusammenfassung: Morbus Bowen (MB) ist eine intraepidermale bösartige Neubildung, die zu einem invasiven Plattenepithelkarzinom der Haut führen kann. Bisher existiert keine Studie, die Therapieoptionen aus randomisierten kontrollierten Studien (RCT) miteinander verglichen hat. In dieser Arbeit wurden Daten aus verfügbaren RCT extrahiert, um läsionsspezifische Heilungsraten und kosmetische Ergebnisse mit Placebo zu vergleichen. Wir durchsuchten MEDLINE, EMBASE, CENTRAL und Studienregister bis 30. September 2024, und schlossen neun Studien mit 672 Patienten und 844 Läsionen ein. Die Therapieoptionen, welche mithilfe einer Netzwerk‐Metaanalyse verglichen wurden, umfassten: Exzision, Imiquimod, photodynamische Therapie (PDT), Laserablation (LA), lasergestützte PDT (LA‐PDT), Kryotherapie und 5‐Fluoruracil (5‐FU). Das Verzerrungsrisiko wurde mithilfe des überarbeiteten Cochrane risk‐of‐bias Tool evaluiert. Die Studie wurde in PROSPERO registriert (CRD42024583966). Alle Therapieoptionen zeigten bessere läsionsspezifische Heilungsraten als Placebo. Bezüglich der initialen Heilungsrate zeigte LA‐PDT die besten Ergebnisse, gefolgt von Exzision und LA. Die Exzision zeigte die besten Ergebnisse bezüglich der langfristigen Heilungsrate, gefolgt von LA‐PDT und PDT. LA‐PDT und 5‐FU hatten das beste, die Exzision das schlechteste kosmetische Ergebnis. Limitationen umfassen ein moderates bis hohes Verzerrungsrisiko sowie Heterogenität der Einzelstudien. Unsere Ergebnisse unterstützen die klinische Entscheidungsfindung, wobei sich LA‐PDT und PDT als effektive Optionen bei guten kosmetischen Ergebnissen erwiesen haben. Die Exzision zeigte jedoch die besten langfrisigen Heilungsraten.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Case examples and prognostic analysis.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Case examples and prognostic analysis.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Time till treatment progression and overall survival stratified by TGFBR1 expression
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Time till treatment progression and overall survival stratified by TGFBR1 expression
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Univariable Cox regression analysis of factors contributing to progression in the cessation cohort.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Univariable Cox regression analysis of factors contributing to progression in the cessation cohort.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Correlation of TGFBR1 expression and immune cell infiltrate.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Correlation of TGFBR1 expression and immune cell infiltrate.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Correlation of site of biopsy with immune cell infiltrate.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Correlation of site of biopsy with immune cell infiltrate.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Cutoff values used to stratify patients
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Cutoff values used to stratify patients
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Purpose:Treatment with immune checkpoint inhibitors (ICI) in advanced melanoma can result in durable responses, yet an algorithm to decide which patients can safely discontinue ICI is still lacking.Experimental Design:We used a multimodal approach combining clinical data, artificial intelligence–based analysis of hematoxylin and eosin–stained whole-slide images of melanoma before ICI start, and gene expression signatures to identify biomarkers for relapse after discontinuing ICI in the absence of treatment progression.Results:Univariable Cox regression analysis identified the best overall response, mRNA expression of six genes, tumor cell density, and the lymphocyte-to-plasma cell ratio as factors predictive of relapse upon the cessation of the ICI. Multivariable Cox regression analysis showed that both TGFBR1 expression and the integral digital pathology parameter–based prognostic system were independently associated with relapse after ICI discontinuation. Training a multivariate adaptive regression spline model achieved the highest overall predictive accuracy of 84.6% for relapse after ICI discontinuation.Conclusions:The identified prognostic markers are fully explainable and easily implementable in routine practice, facilitating risk stratification upon the cessation of ICI therapy.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Purpose:Treatment with immune checkpoint inhibitors (ICI) in advanced melanoma can result in durable responses, yet an algorithm to decide which patients can safely discontinue ICI is still lacking.Experimental Design:We used a multimodal approach combining clinical data, artificial intelligence–based analysis of hematoxylin and eosin–stained whole-slide images of melanoma before ICI start, and gene expression signatures to identify biomarkers for relapse after discontinuing ICI in the absence of treatment progression.Results:Univariable Cox regression analysis identified the best overall response, mRNA expression of six genes, tumor cell density, and the lymphocyte-to-plasma cell ratio as factors predictive of relapse upon the cessation of the ICI. Multivariable Cox regression analysis showed that both TGFBR1 expression and the integral digital pathology parameter–based prognostic system were independently associated with relapse after ICI discontinuation. Training a multivariate adaptive regression spline model achieved the highest overall predictive accuracy of 84.6% for relapse after ICI discontinuation.Conclusions:The identified prognostic markers are fully explainable and easily implementable in routine practice, facilitating risk stratification upon the cessation of ICI therapy.